Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.92 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.35 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.35 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.35 |
| ▸ | GCGR | P47871 | 3/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.34 |
| ▸ | SELP | P16109 | 2/20 | 0.33 |
| ▸ | SELE | P16581 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | RAF1 | P04049 | 2/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13679699 | 1.00 | ABCB1 (0.92) | ABCB1PTPN1MAPTNOX1MAPK13 | |
| SCHEMBL3826448 | 0.96 | ABCB1 (1.00) | ABCB1PTPN1MAPTNOX1MAPK13 | |
| SCHEMBL719050 | 0.96 | ABCB1 (1.00) | ABCB1PTPN1MAPTNOX1MAPK13 | |
| SCHEMBL13780563 | 0.91 | ABCB1 (0.91) | ABCB1PTPN1MAPTNOX1MAPK13 | |
| SCHEMBL3829640 | 0.91 | ABCB1 (0.91) | ABCB1PTPN1MAPTNOX1MAPK13 | |
| SCHEMBL13679665 | 0.91 | ABCB1 (0.91) | ABCB1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL13679717 | 0.91 | ABCB1 (0.91) | ABCB1PTPN1MAPTNOX1MAPK13 | |
| SCHEMBL3824437 | 0.91 | ABCB1 (0.91) | ABCB1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5468480 | 0.91 | ABCB1 (0.89) | ABCB1PTPN1MAPTNOX1MAPK11 | |
| SCHEMBL30357745 | 0.90 | ABCB1 (0.87) | ABCB1PTPN1MAPTNOX1MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1221847-B1 | METHODS OF ENHANCING CHEMOTHERAPY | TAIJI BIOMEDICAL INC (US) | 2009-03-25 | — | — | EP | claimed |
| US-20020147197-A1 | Methods and compositions for enhancing pharmaceutical treatments | TAIJI BIOMEDICAL, INC. | 2002-10-10 | — | — | US | claimed |
| EP-0999835-B1 | IMIDAZOLE DERIVATIVES AS MDR MODULATORS | TAIJI BIOMEDICAL INC (US) | 2009-09-09 | — | — | EP | disclosed |
| EP-2082740-A2 | Use of imidazole derivatives as MDR modulators | Taiji Biomedical, Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-2064951-A1 | Use of a substituted imidazole, derivatives or salts thereof for the preparation of a medicament for the treatment of a cell proliferative disorder | Taiji Biomedical, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| EP-1221847-B1 | METHODS OF ENHANCING CHEMOTHERAPY | TAIJI BIOMEDICAL INC (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20070203215-A1 | Methods & Compositions For Enhancing Pharmaceutical Treatments | TAIJI BIOMEDICAL, INC. (US) | 2007-08-30 | — | — | US | disclosed |
| EP-1221847-A4 | METHODS OF ENHANCING CHEMOTHERAPY | TAIJI BIOMEDICAL INC (US) | 2006-03-22 | — | — | EP | disclosed |
| EP-0999835-A4 | IMIDAZOLE DERIVATIVES AS MDR MODULATORS | ONTOGEN CORP (US) | 2004-08-25 | — | — | EP | disclosed |
| US-20020147197-A1 | Methods and compositions for enhancing pharmaceutical treatments | TAIJI BIOMEDICAL, INC. | 2002-10-10 | — | — | US | disclosed |
| EP-1221847-A1 | METHODS OF ENHANCING CHEMOTHERAPY | Ontogen Corporation (US) | 2002-07-17 | — | — | EP | disclosed |
| WO-2001026467-A1 | METHODS OF ENHANCING CHEMOTHERAPY | ONTOGEN CORPORATION (US) | 2001-04-19 | — | — | WO | disclosed |
| EP-0999835-A1 | IMIDAZOLE DERIVATIVES AS MDR MODULATORS | Ontogen Corporation (US) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999002155-A1 | IMIDAZOLE DERIVATIVES AS MDR MODULATORS | ONTOGEN CORPORATION (US) | 1999-01-21 | — | — | WO | disclosed |
| US-5840721-A | INCREASE SENSITIVITY OF MULTIDRUG RESISTANT TUMOR CELLS TO ANTICANCER AGENTS | ONTOGEN CORPORATION (US) | 1998-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203215-A1 | Methods & Compositions For Enhancing Pharmaceutical Treatments | TUBB3, TUBB1, TUBB2A | ABCB1 21/4885PTPN1 3797/4885MAPT 26/4885 |
| US-20020147197-A1 | Methods and compositions for enhancing pharmaceutical treatments | TUBB3, TUBB1, TUBB2A | ABCB1 14/4885PTPN1 3854/4885MAPT 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.